publication . Preprint . 1991

Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?

Mike Drummond;
Open Access
  • Published: 01 Sep 1991
Abstract
In the summer of 1990, the Australian government took a major step by requiring evidence of cost-effectiveness of new medicines prior to reimbursement by the public health care system. This paper assesses whether the methodological principles behind the guidelines are sound and whether they raise important new logistical and policy implications. It is concluded that, whilst the guidelines may represent ‘the thin end of the wedge’ for the pharmaceutical industry, in that other countries may follow the Australian lead, they also may represent the ‘thin end of the boomerang’ for government. Namely, the development of explicit guidelines for public funding decisions...
Subjects
free text keywords: pharmaceutical industry, Australia, medicines
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue